Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott drug gets NICE guidance

Abbott drug gets NICE guidance

4th July 2008

The National Institute for Health and Clinical Excellence (NICE) has issued guidance on the use of adalimumab – a drug from Abbott branded as Humira – as a treatment for psoriasis in adults.

It recommends the use of the compound as a potential treatment for adults with plaque psoriasis if their condition is severe and if it has not improved with other drugs, such as ciclosporin, methotrexate and psoralen and long-wave ultraviolet radiation.

NICE also recommends the use of adalimumab if there is a medical reason why these latter treatments should not be administered, such as the patient experiencing adverse effects.

It adds that treatment with adalimumab should be continued for longer than 16 weeks only if the condition has been shown to clearly improve during the first four months of treatment.

Professor Peter Littlejohns, clinical and public health director at NICE, said: “Psoriasis is an extremely debilitating disorder that is estimated to affect two per cent of the population.”

He added that studies have shown 60 per cent of sufferers of severe psoriasis have taken time off work due to their condition, with some requiring hospital treatment.

Last month, Abbott announced new data from the extension of the phase III Atlas trial showing the reduction of signs and symptoms of ankylosing spondylitis with the administration of Humira.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.